Lipodystrophy associated with protease inhibitors.
Lipodystrophies, characterized by reduction of subcutaneous fat over part or all of the body surface, are uncommon. Their causes are unknown. Recently, lipodystrophy has been reported in human immunodeficiency virus (HIV)-infected patients taking protease inhibitors, which have been recommended since 1996 as standard therapy for HIV disease in combination with nucleoside analogues. In these cases, lipodystrophy consists of an association of peripheral lipoatrophy with central adiposity. We report four HIV-infected men on protease inhibitors who developed a disfiguring lipodystrophy. In three of them, the protease inhibitor was administered for a mean duration of 21.5 months (range 19-23) with good immunological and virological responses. Patient 4 had been treated for 2 years with successive combinations of protease inhibitors with nucleoside analogues without success. The four patients progressively developed an increase in abdominal girth associated with fat wasting of the face and legs. Two of them had recurrent paronychia of the great toes. Triglyceride levels were moderately increased in all patients, and one had a slightly increased cholesterol level. One patient had elevated glucose and insulin plasma levels during a glucose tolerance test. In two patients, a deep biopsy taken from the thigh showed thinning of the subcutaneous fat without other morphological changes. Computed tomographic scans of the face and abdomen confirmed the loss of almost all subcutaneous fat of the cheek and temporal regions, and abdominal perivisceral fat accumulation. For patients 1-3, the protease inhibitor was replaced by a non-nucleoside reverse transcriptase inhibitor. Nine months later, dysmorphic changes had not regressed, but lipid abnormalities had returned to normal and the paronychia had disappeared.
Panse
I
I
Departments of Dermatology, Internal Medicine V and Histopathology, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, 9 Avenue Charles de Gaulle, 92104 Boulogne, France.
Vasseur
E
E
Raffin-Sanson
M L
ML
Staroz
F
F
Rouveix
E
E
Saiag
P
P
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D019066:Facies; D015497:HIV-1; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced; D008060:Lipodystrophy / Q000097:blood / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010304:Paronychia / Q000139:chemically induced; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*
D011480:Protease Inhibitors